This invention relates to methods and apparatus for use in the separation of fluids into components having different specific gravities. The invention finds particular utility in the centrifugal separation of the components of blood.
Centrifugal separation of blood into components of different specific gravities, such as red blood cells, white blood cells, platelets, and plasma is known from U.S. Pat. No. 5,707,331 (Wells). The apparatus shown in that patent employs a disposable processing tube having two chambers, and blood to be separated into components is placed in one of the chambers. The processing tube is placed in a centrifuge, which subjects the blood to centrifugal forces to separate the components. The supernatant is then automatically decanted into the second of the chambers.
To retain, principally, the red blood cells during the decant of the supernatant, the apparatus disclosed in the Wells patent includes a shelf placed in the first chamber at the expected level of the interface between the red blood cells and the less-dense components, including the plasma. One problem with the arrangement shown in the '331 Wells patent, however, is that the position of the interface varies with the particular proportions of the components (e. g., the hematocrit) of the blood to be processed. Thus, if the shelf is placed at the expected position of the interface for blood of average hematocrit, and the hematocrit of the particular blood being processed is low, the shelf will be above the interface after separation. Such a position of the shelf will hinder the flow of the components near the interface during decanting, thus retaining significant amounts of these components in the first chamber and reducing the separation efficiency of the system.
In accordance with the invention, a movable separator disk, which automatically positions itself at the interface between the separated components, is placed in the first chamber. In the preferred embodiment, the disk is capable of moving vertically and is designed to position itself automatically at the interface between red blood cells and the remaining components in the centrifugal separation of blood.
Decant of the supernatant can be either by gravity drain or by centrifugal transfer, and a main function of the disk is to restrict the flow of the component below it, e. g., red blood cells, during decant. This ensures that the supernatant is not contaminated and increases the efficiency of the process.
The invention contemplates two embodiments for the disk. In one embodiment, the disk is supported on a central shaft such that an annulus is formed between the perimeter of the disk and the interior surface of the first chamber. The dimensions of the annulus are such that the flow of red blood cells through it during decant is restricted such that they do not contaminate the decanted supernatant to any significant degree.
In another embodiment, the disk is arranged on the shaft such that, when the chamber is tilted for gravity decanting, the disk rotates such that one edge of the disk engages the wall of the chamber to block flow of red blood cells.
In either of these embodiments, the specific gravity of the disk and its shape may be chosen so that a major part of the upper surface lies just below the interface, thus facilitating release of the supernatant from the disk during decanting. This upper surface is also preferably curved to match the cylindrical shape the interface assumes during centrifugation.
a is a longitudinal cross-section of a portion of a processing tube chamber and a separator disk in accordance with a first embodiment of the invention.
b is a transverse cross section taken along line 1b-1b of
With reference to
The shaft 6 may not be necessary in all instances, for example, when the bottom of the processing tube is flat. In that instance the disk does not have a central hole.
The disk is preferably made of material having a specific gravity that allows the disk to float at the interface with red blood cells. In the preferred embodiment that specific gravity is about 1.04 (e. g., polystyrene), which is just less than the specific gravity of red blood cells at 70% hematocrit. Thus, when the blood is centrifuged, the disk moves to the interface between the red blood cells and the other components.
The interface will naturally assume a cylindrical shape with a cylindrical radius equal to the distance to the center of rotation of the centrifuge. The disk may be cylindrical, to match the shape of the interface.
In the embodiment shown in
Thus, when the processing tube is rotated to the decant position, the more dense red blood cells, illustrated at 14, that have accumulated below the disk exert a force against the bottom of the disk as they try to flow through the gap 12. This causes the disk 4 to rotate, as shown in
A second embodiment is shown in
Thus, the components of the blood flow through the channel during centrifugation (i. e., at 1000 G), but do not flow appreciably through the channel during decanting at 1 G. This allows the supernatant to be decanted without significant contamination by the red blood cells.
The layer of red blood cells 24 reduces the surface tension between the platelets at the interface 26 and the surface 20 of the disk and facilitates release of the platelets from the disk. This is important to ensure that all of the platelets are decanted, and the small amount of red blood cells that may be decanted along with the supernatant does not generally represent a significant contamination of the supernatant.
Modifications within the scope of the appended claims will be apparent to those of skill in the art.
This application is a continuation of U.S. application Ser. No. 13/680,350 filed on Nov. 19, 2012, which is a continuation of U.S. application Ser. No. 12/453,577 filed on May 15, 2009, which is a divisional of U.S. application Ser. No. 11/206,869 filed Aug. 19, 2005, now U.S. Pat. No. 7,547,272, which is a divisional of U.S. application Ser. No. 10/019,680 filed Jan. 4, 2002, now U.S. Pat. No. 7,077,273, which was the national stage of International Application No. PCT/US01/11732 filed Apr. 27, 2001, which was published in English, and claims priority of U.S. Provisional Application No. 60/200,150 filed Apr. 28, 2000.
Number | Name | Date | Kind |
---|---|---|---|
10140 | Thompson, Jr. | Oct 1853 | A |
280820 | Hickson | Jul 1883 | A |
593333 | Park | Nov 1897 | A |
1818924 | Basmadjian | Aug 1931 | A |
3256977 | Petterson | Jun 1966 | A |
3409165 | Creith | Nov 1968 | A |
3508653 | Coleman | Apr 1970 | A |
3618810 | Wilson | Nov 1971 | A |
3647070 | Adler | Mar 1972 | A |
3661265 | Greenspan | May 1972 | A |
3814248 | Lawhead | Jun 1974 | A |
3814258 | Ayres | Jun 1974 | A |
3852194 | Zine | Dec 1974 | A |
3887466 | Ayres | Jun 1975 | A |
3894950 | Ayres | Jul 1975 | A |
3894951 | Ayres | Jul 1975 | A |
3894952 | Ayres | Jul 1975 | A |
3897337 | Ayres | Jul 1975 | A |
3897343 | Ayres | Jul 1975 | A |
3897940 | Gele | Aug 1975 | A |
3909419 | Ayres | Sep 1975 | A |
3919085 | Ayres | Nov 1975 | A |
3920557 | Ayres | Nov 1975 | A |
3929646 | Adler | Dec 1975 | A |
3931010 | Ayres | Jan 1976 | A |
3931018 | North | Jan 1976 | A |
3931928 | Kido | Jan 1976 | A |
3935113 | Ayres | Jan 1976 | A |
3941699 | Ayres | Mar 1976 | A |
3945928 | Ayres | Mar 1976 | A |
3951801 | Ayres | Apr 1976 | A |
3957654 | Ayres | May 1976 | A |
3972812 | Gresl, Jr. | Aug 1976 | A |
4001122 | Griffin | Jan 1977 | A |
4055501 | Cornell | Oct 1977 | A |
4083788 | Ferrara | Apr 1978 | A |
4088582 | Murty et al. | May 1978 | A |
4152270 | Cornell | May 1979 | A |
4154690 | Ballies | May 1979 | A |
4169060 | Columbus | Sep 1979 | A |
4180465 | Murty | Dec 1979 | A |
4279863 | Friehler | Jul 1981 | A |
4294707 | Ikeda et al. | Oct 1981 | A |
4310430 | Ichikawa | Jan 1982 | A |
4364832 | Ballies | Dec 1982 | A |
4369117 | White | Jan 1983 | A |
4417981 | Nugent | Nov 1983 | A |
4443345 | Wells | Apr 1984 | A |
4487700 | Kanter | Dec 1984 | A |
4492634 | Villa-Real | Jan 1985 | A |
4563332 | Mitchell et al. | Jan 1986 | A |
4588556 | Sarstedt | May 1986 | A |
4608178 | Johansson | Aug 1986 | A |
4707276 | Dodge | Nov 1987 | A |
4751001 | Saunders | Jun 1988 | A |
4818386 | Burns | Apr 1989 | A |
4824560 | Alspector | Apr 1989 | A |
4844818 | Smith | Jul 1989 | A |
4853137 | Ersson | Aug 1989 | A |
4877520 | Burns | Oct 1989 | A |
4946601 | Fiehler | Aug 1990 | A |
4954264 | Smith | Sep 1990 | A |
5053134 | Luderer et al. | Oct 1991 | A |
5282981 | Adams et al. | Feb 1994 | A |
5313779 | Rodgers | May 1994 | A |
5314074 | Inbar et al. | May 1994 | A |
5389265 | Luoma, II | Feb 1995 | A |
5393674 | Levine et al. | Feb 1995 | A |
5454958 | Fiehler | Oct 1995 | A |
5456885 | Coleman et al. | Oct 1995 | A |
5533518 | Vogler | Jul 1996 | A |
5552325 | Nochumson | Sep 1996 | A |
5560830 | Coleman | Oct 1996 | A |
5577513 | Van Vlasselaer | Nov 1996 | A |
5632895 | Tsukagoshi et al. | May 1997 | A |
5632905 | Haynes | May 1997 | A |
5707331 | Wells | Jan 1998 | A |
5707876 | Levine | Jan 1998 | A |
5736033 | Coleman et al. | Apr 1998 | A |
5785925 | U'Ren | Jul 1998 | A |
5840502 | Van Vlasselaer | Nov 1998 | A |
5860937 | Cohen | Jan 1999 | A |
5889584 | Wardlaw | Mar 1999 | A |
5918622 | Perez | Jul 1999 | A |
6280400 | Niermann | Aug 2001 | B1 |
6641517 | Anderson | Nov 2003 | B2 |
7077273 | Ellsworth et al. | Jul 2006 | B2 |
7547272 | Ellsworth | Jun 2009 | B2 |
RE43547 | Ellsworth | Jul 2012 | E |
Number | Date | Country |
---|---|---|
89 10 591.5 | Dec 1989 | DE |
1 106 252 | Jun 2001 | EP |
1 129 779 | Sep 2001 | EP |
56168814 | Dec 1981 | JP |
64044850 | Feb 1989 | JP |
52-126613 | Oct 1997 | JP |
7900135 | Mar 1989 | WO |
Entry |
---|
Order Construing the Terms of U.S. Pat. No. 7,077,273 and RE43,547, DE 65, Filed Sep. 22, 2014. |
Robert E. Marx et al., “Platelet-rich plasma. Growth factor enhancement for bone grafts”, Oral and Maxillofacial Surgery, University of Miami School of Medicine, Jan. 1998. |
Complaint for Patent Infringement, DE 1, 1-1 — 1-3 (Exhibits A-C), Filed Oct. 24, 2012. |
Report to the PTO, DE 3, Filed Oct. 24, 2012. |
Amended Complaint for Patent Infringement, DE 5, 5-1 (Exhibits A-E), Filed Feb. 15, 2013. |
Ceiling Technologies, LLC's Answer, Defenses, and Counterclaims to Plaintiff's Amended Complaint, DE 10, 10-1 (Exhibit A), Filed Apr. 11, 2013. |
Defendant Thermogenesis Corp.'s Answer, Defenses, and Counterclaims to Plaintiff's Amended Complaint, DE 12, 12-1 (Exhibit A), Filed Apr. 11, 2013. |
Second Amended Complaint for Patent Infringement, DE 32, 32-1 (Exhibit A-E) Filed Jan. 10, 2014. |
Amended Report to the PTO, DE 35, Filed Jan. 13, 2014. |
Defendant Thermogenesis Corp.'s Answer, Defenses, and Counterclaims to Plaintiff's Second Amended Complaint, DE 37, Filed Feb. 28, 2014. |
Ceiling Technologies, LLC's Answer, Defenses, and Counterclaims to Plaintiff's Second Amended Complaint, DE 38, Filed Feb. 28, 2014. |
Cesca's Therapeutics Inc., and Ceiling Technologies, LLC's Response to Plaintiff Harvest Technologies Corporation's First Set of Joint Interrogatories to Defendants Cesca Therapeutics Inc. and Ceiling Technologies, LLC (Nos. 1-6), May 1, 2014. |
Joint Claim Chart, DE 49, 49-1, Filed May 21, 2014. |
Defendants Cesca's and Ceiling's Opening Claim Construction Brief, DE 50, Filed May 30, 2014. |
Harvest Technologies Corporation's Opening Claim Construction Brief, DE 51, Filed May 30, 2014. |
Amended Joint Claim Chart, DE 52, 52-1 (Exhibit A), Filed Jun. 9, 2014. |
Defendants Cesca's and Ceiling's Answering Claim Construction Brief, DE 54, Filed Jun. 27, 2014. |
Harvest Technologies Corporation's Answering Claim Construction Brief, DE 55, Filed Jun. 27, 2014. |
Joint Appendix of Intrinsic Evidence, DE 56, 56-1—56-22, Filed Jun. 27, 2014. |
Harvest Markman Hearing Transcript, DE 58, Jul. 9, 2014. |
Cesca Therapeutics Inc.'S First Supplemental Responses to Plaintiff Harvest Technologies Corporation'S First Set of JT Interrogatories to Defendants Cesca Therapeutics Inc. and Celling Technologies, LLC (Nos. 1-6) (Appendices B01-08 and C), filed Dec. 19, 2014. |
Celling Technologies, LLC'S First Supplemental Responses to Plaintiff Harvest Technologies Corporation'S First Set of JT Interrogatories to Defendants Cesca Therapeutics Inc. and Celling Technologies, LLC (Nos. 1-6) (Appendices B01-08) and C, filed Dec. 19, 2014. |
Stipulated Motion and [Proposed] Order for Dismissal With Prejudice, filed Aug. 20, 2015, 2 pages. |
Number | Date | Country | |
---|---|---|---|
20140131292 A1 | May 2014 | US |
Number | Date | Country | |
---|---|---|---|
60200150 | Apr 2000 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11206869 | Aug 2005 | US |
Child | 12453577 | US | |
Parent | 10019680 | US | |
Child | 11206869 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13680350 | Nov 2012 | US |
Child | 14160809 | US | |
Parent | 12453577 | May 2009 | US |
Child | 13680350 | US |